Last reviewed · How we verify
subcutaneous immunotherapy with DPT extract — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
subcutaneous immunotherapy with DPT extract (subcutaneous immunotherapy with DPT extract) — Roxall Medicina España S.A.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| subcutaneous immunotherapy with DPT extract TARGET | subcutaneous immunotherapy with DPT extract | Roxall Medicina España S.A | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- subcutaneous immunotherapy with DPT extract CI watch — RSS
- subcutaneous immunotherapy with DPT extract CI watch — Atom
- subcutaneous immunotherapy with DPT extract CI watch — JSON
- subcutaneous immunotherapy with DPT extract alone — RSS
Cite this brief
Drug Landscape (2026). subcutaneous immunotherapy with DPT extract — Competitive Intelligence Brief. https://druglandscape.com/ci/subcutaneous-immunotherapy-with-dpt-extract. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab